Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia

Lymphoma Clinical Trial

— RAISE  

Official title:

An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin¿s Lymphoma and Acute Leukemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04349306
• Other study ID #: RASBUL09107
• Secondary ID: U1111-1233-0737
• Status: Completed
• Phase: Phase 4
• Start date: May 14, 2020
• Est. completion date: March 12, 2021

Study information

• Verified date: April 2022
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective: To evaluate safety of rasburicase in pediatric patients with NHL and AL Secondary Objective: To assess efficacy of rasburicase for prevention and treatment of hyperuricemia

Description:

Study duration per participants is approximatively 14 days including a 5-day treatment period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: March 12, 2021
• Est. primary completion date: March 12, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 18 Years

Eligibility

Inclusion criteria :

• Patient or parent/legal guardian is willing and able to provide signed informed consent, and if required, the patient is willing to provide assent.
• Children or adolescent aged 2 to 18 years old (inclusive) at time of signing of informed consent.
• At screening, the patient is expected to have a minimum life expectancy of 45 days and has a performance status (PS) no greater than 3 on the Eastern Cooperative Oncology Group (ECOG) scale, or a PS no less than 30 on the Lansky score as per the Investigator's preference (see Appendix D for ECOG and Lansky scale).
• Newly diagnosed NHL or AL who is at the initiation of or during the first cycle of chemotherapy,baseline blood uric acid greater than 8 mg/dL (473 mol/L) at screening.
• If newly diagnosed NHL patient with blood uric acid no greater than 8 mg/dL at screening, the patient must be diagnosed with Stage III or IV non-Hodgkin's lymphoma with high tumor burden which will be high risk of TLS defined, with one or more of following below: A. Burkitt lymphoma/leukemia or -lymphoblastic lymphoma, and/or B. Has at least one of lymph node or tumor, the diameter >5 cm, and/or C. Lactate dehydrogenase (LDH) no less than 2 times the upper limit of normal (ULN).
• If newly diagnosed AL patient is with blood uric acid no greater than 8 mg/dL at the screening but with a high risk of TLS defined with one of the following below criteria: A. White blood cell (WBC) no less than 100.0 10-9/L, or B. WBC < 100.0 10-9/L with LDH no less than 2 ULN.
• The patient will receive the chemotherapy, and will be confined in hospital for at least 14 days after first dose of rasburicase.

Exclusion criteria:

• Acute promyelocytic leukemia
• Patient who has been treated or planned to receive allopurinol within 72 hours of rasburicase administration.
• Patients with abnormal liver or renal function: alanine aminotransferase (ALT) >5 ULN, total bilirubin >3 ULN, serum creatinine >3 ULN.
• Documented history of hereditary allergy or asthma.
• Patients with known deficiency of glucose-6-phosphate dehydrogenase (G6PD), or a history of hemolytic disease or methemoglobinemia.
• Patients with severe infection or active bleeding.
• Previous therapy with urate oxidase.
• Hypersensitive reaction against rasburicase or any of the other ingredients of the study drug.
• Patient is not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or patients potentially at risk of noncompliance to study procedures.
• Pregnant or breastfeeding woman.
• Woman of childbearing potential (WOCBP) not protected by highly-effective method(s) of birth control and/or who are unwilling or unable to be tested for pregnancy (see contraceptive guidance in Appendix A).
• Male participant with a female partner of childbearing potential not protected by highly-effective method(s) of birth control The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Hyperuricemia
• Lymphoma

Intervention

Drug:
• RASBURICASE SR29142
Pharmaceutical form:solution for infusion Route of administration: intravenous

Locations

Country	Name	City	State
China	investigational site CHINA	China

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of AEs and SAEs	Incidence of AE or SAE will be summarized as the number and percentage of subjects who experienced any AE or SAE during the treatment period.	Day 1 to Day 7
Secondary	Number of responders after completion of rasburicase treatment under chemotherapy	Response will be defined as achievement of normal uric acid levels (= 8.0 mg/dL) in those patients whose uric acid levels are >8.0 mg/dL.	Day 1 to Day 7
Secondary	Proportion of patients who can maintain the normal uric acid levels throughout the study	In those patients whose baseline plasma uric acid levels are = 8 mg/dL but with a high risk of TLS.	Day 1 to Day 7
Secondary	Percentage of the maximum decreasing degree of plasma uric acid level from baseline		Day 1 to Day 7